Hypoxia-inducible factor 1 in lower limb ischemia

Area of Science:

• Vascular Biology
• Molecular Medicine
• Physiology

Background:

• Peripheral vascular disease (PVD) is prevalent in Western countries, associated with significant morbidity and mortality.
• Critical limb ischemia (CLI), the advanced stage of PVD, is increasingly seen due to longer life expectancy.
• Despite medical advances, lower limb amputation remains common for CLI patients.

Purpose of the Study:

• To review the role of hypoxia-inducible factor (HIF)-1 in peripheral vascular disease (PVD).
• To explore the therapeutic potential of HIF-1 in managing ischemic diseases, particularly in skeletal muscle.

Main Methods:

• Literature review focusing on hypoxia-inducible factor (HIF)-1.
• Analysis of studies on angiogenesis and skeletal muscle metabolic adaptation in response to hypoxia.
• Examination of HIF-1's role in cellular and systemic pathophysiology.

Main Results:

• Hypoxia-inducible factor (HIF)-1 regulates genes involved in cellular adaptation to low oxygen.
• HIF-1 is crucial for endogenous angiogenesis and metabolic changes in ischemic skeletal muscle.
• While HIF-1's angiogenic role is studied, its function in skeletal muscle metabolism in PVD is less understood.

Conclusions:

• HIF-1 is a master regulator of oxygen homeostasis with significant implications for PVD.
• Understanding HIF-1's role in skeletal muscle metabolism is critical for developing new PVD therapies.
• Targeting HIF-1 pathways may offer novel therapeutic strategies for critical limb ischemia.